Icon

UKONIQ - (200MG)

UMBRALISIB TOSYLATE None
200MG
Less Than $1000 mn
None None
None None
None None
UKONIQ is a kinase inhibitor indicated for the treatment of adult patients with: • Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. • Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Yes
UKONIQ Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
*** *********

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.